Amid the push for reshoring and fiscal reform, the tariffs are part of a broader effort to rebalance trade and fund domestic initiatives, as the pharma sector awaits potential levies of its own.
The company joins a wave of global pharma companies reshoring operations to strengthen the US supply chain and meet patient needs through domestic innovation and capacity.
The collaborative research initiative will be focused on advancing approaches to enhance the therapeutic efficacy of regulatory T cells and tumor-infiltrating lymphocytes.
The new system meets the increasing demand for faster, more precise processes that enhance quality while boosting efficiency in the pharma manufacturing industry.